Phe-Phe(2-Me)-NH2 | 1204418-13-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Phe-Phe(2-Me)-NH2
• 英文别名: (2S)-2-amino-N-[(2S)-1-amino-3-(2-methylphenyl)-1-oxopropan-2-yl]-3-phenylpropanamide
• CAS: 1204418-13-2
• 化学式: C₁₉H₂₃N₃O₂
• 分子量: 325.411
• InChiKey: GLOHCSYXIQCSMI-IRXDYDNUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  98.2
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  Fmoc-L-苯丙氨酸 、 FMOC-L-2-甲基苯丙氨酸 在 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 哌啶 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以38%的产率得到Phe-Phe(2-Me)-NH2
  参考文献：
  名称：

  Constrained H-Phe-Phe-NH₂ Analogues with High Affinity to the Substance P 1–7 Binding Site and with Improved Metabolic Stability and Cell Permeability

  摘要：

  We recently reported the discovery, of H-Phe-Phe-NH2 as a small and high affinity ligand for the substance P 1-7 (SP1-7, H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-OH) specific binding site and its intriguing ability to reduce neuropathic pain. With the overall aim to develop stable and orally bioavailable SP1-7 mimetics, the dipeptide was chosen as a lead compound. Herein the structure activity relationship (SAR) of a set of modified H-Phe-Phe-NH2 analogues is presented together with their potential active uptake by PEPT1 transporter, intestinal permeability, and metabolic stability. Local constraints via peptide backbone methylation or preparation of cyclized analogues based on pyrrolidine were evaluated and were shown to significantly improve the in vitro pharmacokinetic properties. The SAR was rationalized by deriving a plausible binding pose for the high affinity ligands. Rigidification using a 3-phenylpyrrolidine moiety in the C-terminal of H-Phe-Phe-NH2 resulted in high affinity and improved intrinsic clearance and intestinal epithelial permeability.

  DOI：

  10.1021/jm400209h

文献信息

• [EN] THERAPEUTIC METHODS AND COMPOSITIONS EMPLOYING PEPTIDE COMPOUNDS<br/>[FR] PROCÉDÉS THÉRAPEUTIQUES ET COMPOSITIONS UTILISANT DES COMPOSÉS PEPTIDIQUES
  申请人：NYBERG FRED

  公开号：WO2010004535A2

  公开（公告）日：2010-01-14

  Methods for alleviating pain in a mammal, methods for alleviating a symptom associated with cessation or withdrawal from an addiction to a habit-forming drug in a mammal, methods for alleviating inflammation in a mammal, and methods for alleviating a symptom associated with a neuropsychiatric disorder, wherein the neuropsychiatric disorder is a cognitive deficiency or anxiety, in a mammal, comprise administering to the mammal a therapeutically effective amount of a peptide compound of Formula (I), Formula (II), or Formula (III), or a pharmaceutically acceptable salt thereof: Formula (I), Formula (II), Formula (III) as described herein. Pharmaceutical compositions which may be employed, inter alia, in such methods comprise a peptide compound of Formula (I), Formula (II), or Formula (III) and a pharmaceutically acceptable carrier.